NRX Pharmaceuticals
NRXP
6 hedge funds and large institutions have $310K invested in NRX Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.02% less ownership
Funds ownership: 0.05% → 0.03% (-0.02%)
10% less capital invested
Capital invested by funds: $345K → $310K (-$35K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$259K |
| 2 |
WAP
Wealthcare Advisory Partners
West Chester,
Pennsylvania
|
+$13.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$288K |
| 2 |
Morgan Stanley
New York
|
-$25K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.43K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $253K | +$259K | +715 | New |
|
|
2
Morgan Stanley
New York
| $24K | -$25K | -69 | -51% |
|
|
WAP
3
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| $13K | +$13.8K | +38 | New |
|
|
4
Osaic Holdings
Scottsdale,
Arizona
| $12K | -$5.43K | -15 | -30% |
|
5
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $4K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $4K | +$3.62K | +10 | New |
|
|
HF
7
HRT Financial
New York
| – | -$288K | -1,181 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$6K | -23 | Closed |
|
|
WAM
9
Wolverine Asset Management
Chicago,
Illinois
| – | -$2K | -10 | Closed |
|
NRXP Hedge Fund Activity: Q1 2021 in Review
6 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2021, worth a combined $310K — down 10% from $345K a quarter earlier.
Fund positioning in NRXP was balanced in Q1 2021: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $259K. The largest seller was HRT Financial, exiting entirely with an estimated $288K sold.
- 6 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $310K of NRX Pharmaceuticals stock for Q1 2021, down 10% quarter-over-quarter.
- 3 funds opened new NRX Pharmaceuticals positions in Q1 2021 and 3 closed out, a net change of 0 holders.
- The largest NRX Pharmaceuticals buyer in Q1 2021 was Jane Street, an estimated $259K added.
- The largest NRX Pharmaceuticals seller in Q1 2021 was HRT Financial, an estimated $288K sold.
Based on aggregated 13F filings for Q1 2021.